On January 4, 2008, ACTAVIS ELIZABETH received approval from the FDA for the ANDA for the unspecified drug substance, signaling an expansion of its product pipeline and competitive position in the generic pharmaceutical market. The approval is expected to foster growth and capitalize on evolving market dynamics in the therapeutics sector.